Abstract Number: 2378 • 2013 ACR/ARHP Annual Meeting
Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Mavrilimumab (CAM-3001)…Abstract Number: 2379 • 2013 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients With Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation Of Etanercept Is Superior Both Clinically and Radiographically To Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
Background/Purpose: The randomized clinical trial “DOSERA” has shown that in patients receiving concomitant methotrexate (MTX) therapy, continuation of etanercept (ETN) at 50 mg wkly is…Abstract Number: 2380 • 2013 ACR/ARHP Annual Meeting
Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?
Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for…Abstract Number: 2381 • 2013 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
Background/Purpose: GLPG0634 is an oral, selective inhibitor of Janus kinase 1 (JAK1). JAKs signal for cytokines and growth factors, including those involved in rheumatoid arthritis…Abstract Number: 2382 • 2013 ACR/ARHP Annual Meeting
B Cell Analysis Is An Essential Tool To Anticipate Clinical Relapse In Rheumatoid Arthritis Patients Treated With Rituximab
Background/Purpose: Rituximab is a safe and effective treatment in rheumatoid arthritis (RA), however the current treatment regimen requires to wait for a clinical relapse before…Abstract Number: 2383 • 2013 ACR/ARHP Annual Meeting
A Useful Mathematical Model Able To Predict The Early Response To Tocilizumab In Rheumatoid Arthritis
Background/Purpose: In the last few year the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…Abstract Number: 2384 • 2013 ACR/ARHP Annual Meeting
Variability In Patient Characteristics and Outcomes In Rheumatoid Arthritis Upon Infliximab Treatment Based On The Size Of Biologic Treatment Registry Site
Background/Purpose: Efficacy of TNFi agents in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. Variations with respect to patient…Abstract Number: 2385 • 2013 ACR/ARHP Annual Meeting
Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions
Background/Purpose: Interleukin-6 (IL-6), a pleiotropic cytokine, drives cell functions by binding to membrane-bound IL-6 receptor (IL-6R, classical signaling) or to soluble IL-6R (sIL-6R, trans-signaling) and…Abstract Number: 2386 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Therapy In Rheumatoid Arthritis: 12 Years Follow-Up Cohort
Background/Purpose: After more than a decade of biological agents (BA) use for the treatment of rheumatoid arthritis (RA), it is necessary a thorough knowledge of…Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…Abstract Number: 2388 • 2013 ACR/ARHP Annual Meeting
Predictive Factors Of Relapse Or Persistent Stable Remission For Rheumatoid Arthritis (RA) Patients In Remission in a TNF Blocker-Spacing Strategy Trial (STRASS Trial)
Background/Purpose: The STRASS trial was a 18-month randomized controlled trial, conducted in established RA patients in DAS28 remission with etanercept (ETA) or adalimumab (ADA), comparing…Abstract Number: 2389 • 2013 ACR/ARHP Annual Meeting
Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency
Background/Purpose: In AA amyloidosis patients with RA taking oral medicines such as methotrexate and prednisolone, it is generally accepted that the renal function deteriorates gradually…Abstract Number: 2390 • 2013 ACR/ARHP Annual Meeting
Low Dose Of Tocilizumab Can Be Effective In RA Patients Who Achieve Remission.
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6-receptor antibody, is used for the treatment of moderate to severe rheumatoid arthritis (RA) in adults with inadequate response or intolerance…Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…Abstract Number: 2352 • 2013 ACR/ARHP Annual Meeting
Evaluation and Management Of Laboratory Abnormalities During Tocilizumab Treatment Either As Monotherapy Or In Combination With Dmards In RA Patients: Findings From The ACT-STAR Study
Background/Purpose: Laboratory values from phase III clinical trials of tocilizumab (TCZ) in patients with RA were the basis of the recommendations for monitoring and managing…
ACR Meeting Abstracts